PRESS RELEASES

SELLAS Life Sciences Announces Positive Pivotal Phase 3 REGAL Trial Data Showing Immunotherapeutic Cancer Vaccine, Galinpepimut-S (GPS), Demonstrated a Statistically Significant and Clinically Meaningful Improvement in Overall Survival in Patients with Acute Myeloid Leukemia

– REGAL trial met its primary endpoint with GPS demonstrating statistically significant and clinically meaningful reduction in risk of death by 41% with median overall survival of 24.0 months versus 14.7 months for best available treatment, and a hazard ratio of 0.59 (p=0.035) – – Company plans to meet with

Read More

Digital Realty Innovation Lab (DRIL) Launches in Singapore, Enabling Asia Pacific Enterprises to Validate and Scale AI-Ready Infrastructure

SINGAPORE, Nov. 17, 2026 (GLOBE NEWSWIRE) — Digital Realty (NYSE: DLR), the world’s largest cloud- and carrier-neutral data center platform, today announced the opening of the Digital Realty Innovation Lab (DRIL) in Singapore. The facility provides enterprises across Asia Pacific with a real-world colocation environment inside a live data center

Read More

YYForce Sets Operating Priorities Across AI Workforce, Robotics and Facility Management

Company Targets Commercial Robotics Scaling, Humanoid R&D and Disciplined Cash Generation SINGAPORE, Nov. 16, 2026 (GLOBE NEWSWIRE) — YYForce Inc. (NASDAQ: YFOR) (“YYForce” or the “Company”), an AI-enabled frontline workforce, robotics, and facility solutions provider, today outlined its operating priorities across frontline staffing, integrated facility management and commercial robotics. YYForce

Read More